If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Area of Expertise

Dr. Long Wong believes that being an excellent family medicine physician requires several strengths—good communication with patients, superb medical knowledge, and excellent techniques. Doing the job well also calls for collaboration with specialty physicians. In addition, Dr. Wong says the treatment plan for each patient needs to be individualized.
He is an American Board of Family Medicine (ABFM) certified physician and an American Medical Association (AMA) recognized physician. Dr. Wong is a member of several professional organizations, including the AMA, Texas Medical Association (TMA), and American Academy of Family Physicians.
Dr. Wong also serves as a Master of Medical Science Student Shadow for UNT Health Science Center-sponsored activities.

Education/Academic qualification

MD , Norman Bethune Medical University

PhD in Pharmacology, University of Minnesota

Fingerprint Dive into the research topics where Long Wong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Cyclic ADP-Ribose Medicine & Life Sciences
5,6-dihydro-5-azacytidine Medicine & Life Sciences
Mesothelioma Medicine & Life Sciences
Methylation Medicine & Life Sciences
Adenosine Diphosphate Ribose Medicine & Life Sciences
Warfarin Medicine & Life Sciences
Secondary Prevention Medicine & Life Sciences
Biological Assay Medicine & Life Sciences

Projects 2018 2021

Research Output 1997 2009

  • 169 Citations
  • 5 h-Index
  • 5 Article
  • 1 Short survey

Warfarin therapy not warranted for secondary prevention of CVD: Warfarin is no better than aspirin for preventing recurrent ischemic strokes.

Wong, L. & Criswell, D., 1 Dec 2009, In : Evidence-Based Practice. 12, 12, p. 1-2 2 p.

Research output: Contribution to journalShort surveyResearchpeer-review

Warfarin
Secondary Prevention
Aspirin
Stroke
Therapeutics
10 Citations (Scopus)

Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: Results of cancer and leukemia group B 159904

Kratzke, R. A., Wang, X., Wong, L., Kratzke, M. G., Green, M. R., Vokes, E. E., Vogelzang, N. J., Kindler, H. L. & Kern, J. A., 1 Jan 2008, In : Journal of Thoracic Oncology. 3, 4, p. 417-421 5 p.

Research output: Contribution to journalArticleResearchpeer-review

5,6-dihydro-5-azacytidine
Mesothelioma
Methylation
Leukemia
Neoplasms
66 Citations (Scopus)

Inactivation of p16INK4a expression in malignant mesothelioma by methylation

Wong, L., Zhou, J., Anderson, D. & Kratzke, R. A., 1 Nov 2002, In : Lung Cancer. 38, 2, p. 131-136 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Mesothelioma
Methylation
p16 Genes
Cytidine
5,6-dihydro-5-azacytidine
54 Citations (Scopus)

Cyclic 3-deaza-adenosine diphosphoribose: a potent and stable analog of cyclic ADP-ribose

Wong, L., Aarhus, R., Cheung Lee, H. & Walseth, T. F., 16 Nov 1999, In : Biochimica et Biophysica Acta - General Subjects. 1472, 3, p. 555-564 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Cyclic ADP-Ribose
Adenosine Diphosphate Ribose
Calcium
15 Citations (Scopus)

Bioassay for determining endogenous levels of cyclic ADP-ribose

Walseth, T. F., Wong, L., Graeff, R. M. & Lee, H. C., 1 Jan 1997, In : Methods in Enzymology. 280, p. 287-294 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Cyclic ADP-Ribose
Biological Assay